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Protein synthesis in mammalian cells can be regulated through phosphorylation/dephosphorylation of the a subunit of initiation factor 2, eIF-2. 
Two specific kinases have been identified that apparently phosphorylate the same site(s). Controversy exists as to whether serine-48 is a phosphoryla- 
tion site in addition to serine-5 1. A recent publication is discussed that, in this author’s view, answers the question of the phosphorylation sites. 
It is suggested that phosphorylation procedes equentially with serine-51 being the first and serine-48 the second phosphorylation site. Phosphoryla- 
tion of both sites is required for inhibition of protein synthesis. 
Protein synthesis regulation; Initiation factor 2, Phosphorylation site 
The phosphorylation site(s) on mammalian eIF-2a, 
the OL subunit of protein synthesis initiation factor 2, 
have been controversial. Phosphorylation by either of 
two different specific kinases leads to inhibition of pro- 
tein synthesis by a common mechanism as considered in 
detail in [ 11. The two enzymes are the heme-controlled 
eIF-2a kinase and the double-stranded (ds)RNA- 
dependent kinase. Both kinases occur in rabbit 
reticulocytes (references in [I]), but the latter also is 
found in a number of interferon-sensitive mammalian 
cells [2-41. The two kinases have been reported to 
phosphorylate the same sites on eIF-2cr [5-71. The 
following discussion is based on this premise. 
By direct phosphopeptide analysis and sequencing we 
determined [S] that serine-48 is a phosphorylation site 
in eIF-2a for the heme-controlled reticulocyte kinase. 
In collaboration with B. Kemp [9], a synthetic peptide 
was used that comprised amino acids 41-54 of eIF-2a 
containing serine-residues at positions 48 and 51. In 
vitro phosphorylation of this peptide resulted only in 
modification of serine-5 1. Increased phosphorylation 
of serine-5 1 relative to serine-48 was observed in eIF-2a 
after stimulation of the reticulocyte eIF-2a kinase by 
spectrin-subunits in vitro [9]. Colthurst et al. [7] found 
only serine-51 as a phosphorylation site in eIF-2a! for 
either kinase. 
Hershey and coworkers cloned and sequenced human 
eIF-2ol [lo] and by site-directed mutagenesis prepared 
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mutant cDNAs encoding functionally active eIF-2o 
with alanine at either position 48 or 5 1 [ 111. The in vitro 
expressed mutant forms were translated in the 
reticulocyte lysate and their phosphorylation was 
studied when the heme-controlled or the dsRNA- 
activated kinase was present. The mutant Ala-48 form 
was phosphorylated, the mutant Ala-51 species was 
not. The authors concluded serine-51 to be the only 
phosphorylation site for either kinase on the eIF-2cr 
subunit. 
A definite answer to the controversy regarding 
phosphorylation site(s) on eIF-2o may lie in a recently 
published paper by Davies et al. [12]. These authors 
studied the in vivo effects of the mutant eIF-2o forms 
described above on complementing deletion forms of 
adenovirus to support viral protein synthesis in infected 
human 293 cells. Adenovirus mutants defective in the 
synthesis of a small RNA (VA1 RNA) are described and 
discussed in a recent review [4]. The defect allows host 
cells to activate the interferon-induced dsRNA- 
dependent eIF-2a kinase, since it has been 
demonstrated that adenovirus-encoded VA1 RNA in- 
teracts with and prevents activation of this kinase [3]. 
Davies et al. [12] introduced the plasmids containing 
the eIF-2a mutant forms into 293 cells, then studied 
defective adenovirus replication and protein synthesis 
in these transformants. They report that a cell line car- 
rying the eIF-2o (Ala-51) mutant that cannot be 
phosphorylated will relieve inhibition of viral protein 
synthesis. The authors are surprised by the finding that 
expression of the eIF-2a (Ala-48) mutant in another cell 
line shows the same effect. They are puzzled by this 
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finding because this mutant eIF-2a expressed in the 
virus-infected cells is phosphorylated by the dsRNA- 
dependent kinase. It should be noted that all cell lines 
irrespective of the level of eIF-2o synthesis during a 
30-min pulse exhibited similar levels of eIF-2a protein 
monitored by immunoblot analysis [ 121. 
In a previous publication [13], Kaufman et al. in- 
dicated already that expression of serine-to-alanine at 
either residue 48 or residue 51 could substitute for VA 
RNA and promote translation of plasmid-derived 
mRNAs in COS-1 cells. The data presented by these 
authors [12,13] may be interpreted in the following 
way. Both serine-48 and serine-51 can be phospho- 
rylated by the eIF-2a kinases but phosphorylation pro- 
ceeds in a sequential order. First serine-51 is phosphory- 
lated (which can be accomplished even in a synthetic 
peptide [9]), and then subsequently serine-48 is 
phosphorylated. For biological effects, i.e. inhibition 
of protein synthesis, both sites have to be 
phosphorylated. 
How can the data published on eIF-2o phosphoryla- 
tion be reconciled with this interpretation? Our first 
report on the phosphorylation site for the heme- 
regulated eIF-2a kinase [8] identified only serine-48; 
however, it did not exclude serine-51. This site was not 
detected because not all tryptic phosphopeptides or 
derived chymotryptic peptides could be sequenced. 
Analyses of eIF-2ar from cells or lysates after dif- 
ferent incubation conditions by isoelectric focussing 
have been interpreted generally to indicate one 
phosphorylated and one unphosphorylated form (e.g. 
[14, 151). However, data presented in [16], p. 5492, may 
indicate more than two eIF-2cr forms. 
Analyses of eIF-2a isolated from reticulocyte lysates 
that had been incubated in the presence or absence of 
hemin deserve more careful consideration. Scorsone et 
al. [15] used monoclonal antibodies to identify eIF-2a 
(phosphorylated or unphosphorylated) after separating 
polypeptides in isoelectric focussing gels. They separate 
two forms, eIF-2a and eIF-ZaP, from the reticulocyte 
lysate regardless of whether it was incubated with or 
without hemin or with exogenously added eIF-2a! 
kinase. Jagus and Safer [17], on the other hand, purify 
eIF-2, then separate three eIF-2a! forms from hemin- 
deficient lysates applying the same techniques. These 
authors also quantitate the inorganic phosphate content 
of eIF-2a! isolated from hemin-supplemented and 
hemin-deficient lysates. They find 0.96-l .05 mol 
phosphate/m01 eIF-2cr in the former, and 1.25-1.30 
mol phosphate/m01 eIF-2a in the latter case. In vitro in- 
cubation of the same eIF-2 preparations with 
[y-32P]ATP and heme-controlled eIF-2ar kinase leads to 
additional incorporation of 0.95 to 1.03 mol 
phosphate/mol eIF-2a into eIF-2 isolated from the 
former and 0.69-0.74 mol phosphate/m01 eIF-2a from 
the latter lysates. In an earlier paper [ 181 it was conclud- 
ed that one mole of phosphate was incorporated into 
eIF-2a by in vitro incubation of eIF-2 with [T-~~P]ATP 
and the heme-controlled kinase. However, the data 
presented indicate more than one (up to about 1.2) mol 
phosphate incorporated per mol eIF-2cr. 
The data cited may indicate the ambiguity of the ex- 
tent of eIF-2o phosphorylation both in vivo and in 
vitro. They do not exclude the presence of two 
phosphorylation sites. However, in my view, the recent 
data published by Davies et al. [I21 unequivocally 
demonstrate the biological importance of both 
serine-48 and serine-51 as phosphorylation sites to exert 
translational control. 
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